SCHEMBL3416845

SCHEMBL3416845

[CH]1c2ccccc2C=CN1N1[CH]c2ccccc2C=C1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.31
CCL2 P13500 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5827695 0.74 LMNA (0.30)
SCHEMBL12076336 0.69 P2RX4 (0.32) BRD4CCL2
SCHEMBL13236583 0.69 MEN1 (0.50) BRD4CCL2GAAMAPT
SCHEMBL29418986 0.67 MAPT (0.53) GAAMAPT
SCHEMBL33554 0.67
SCHEMBL3767165 0.67 MAPT (0.53) GAAMAPT
SCHEMBL29398195 0.67
SCHEMBL29375766 0.67 MAPT (0.53) GAAMAPT
SCHEMBL4664953 0.66 NOTUM (0.39) BRD4CCL2
Water SCHEMBL9798116 0.64 MAPT (0.50) GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709263-B2 Lanthanide complexes preparation and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-05-04 US claimed
US-20080044923-A1 Lanthanide Complexes Preparation and Uses Thereof UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) 2008-02-21 US claimed
US-7838299-B2 Lanthanide complexes, preparation and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-11-23 US disclosed
US-20100216252-A1 Lanthanide Complexes, Preparation and Uses Thereof UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) 2010-08-26 US disclosed
US-7709263-B2 Lanthanide complexes preparation and uses thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-05-04 US disclosed
US-20080044923-A1 Lanthanide Complexes Preparation and Uses Thereof UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080044923-A1 Lanthanide Complexes Preparation and Uses Thereof NR2E3, GALR3, NR0B2 BRD4 1041/4885CCL2 564/4885GAA 4589/4885
US-20100216252-A1 Lanthanide Complexes, Preparation and Uses Thereof NR2E3, NR0B2, GALR3 BRD4 878/4885CCL2 686/4885GAA 4590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.